Inhibition of CCl4-induced liver inflammation and fibrosis by a NEU3 inhibitor
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0308060 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Darrell Pilling und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Texas A&M University, College Station, Texas, United States of America. Hauptthemen laut MEDLINE: Carbon Tetrachloride, Neuraminidase, Liver Cirrhosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Arnold and Mabel Beckman Foundation.
Abstract (Originalsprache)
Sialic acids are located on the ends of many glycoconjugates and are cleaved off by enzymes called sialidases (neuraminidases). Upregulation of neuraminidase 3 (NEU3) is associated with intestinal inflammation and colitis, neuroinflammation, and lung fibrosis. Genetic ablation of NEU3 or pharmacological inhibition of NEU3 reduces lung fibrosis in mice. To determine if inhibiting NEU3 can inhibit liver fibrosis in the commonly-used CCl 4 model, in this report, we examined the effects of injections of the NEU3 inhibitor 2-acetyl pyridine (2AP). 2AP inhibited CCl 4 -induced weight loss in female but not male mice. 2AP attenuated CCl 4 -induced liver inflammation and fibrosis in male and female mice, but did not affect CCl 4 -induced steatosis. After CCl 4 treatment, female but not male mice had significant increases in liver neutrophils, and 2AP attenuated this response. 2AP also reversed CCl 4 -induced liver desialylation and CCl 4 -induced increased expression of NEU3. Patients with pulmonary fibrosis have increased desialylation of some serum proteins, and elevated serum levels of NEU3. We find that sera from patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have elevated desialylation of a serum protein and patients with NAFLD have increased levels of NEU3. These data suggest that elevated levels of NEU3 may be associated with liver inflammation and fibrosis, and that in mice this is ameliorated by injections of a NEU3 inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biology, Texas A&M University, College Station, Texas, United States of America.
ORCID-Profile: Darrell Pilling, Trevor C Martinez, Richard H Gomer
Förderung
- NHLBI NIH HHS
- Arnold and Mabel Beckman Foundation
Zitieren
APA
Pilling, D., Martinez, T. C., & Gomer, R. H. (2024). Inhibition of CCl4-induced liver inflammation and fibrosis by a NEU3 inhibitor. PLOS ONE. https://doi.org/10.1371/journal.pone.0308060
Vancouver
Pilling D, Martinez TC, Gomer RH. Inhibition of CCl4-induced liver inflammation and fibrosis by a NEU3 inhibitor. PLOS ONE. 2024. doi:10.1371/journal.pone.0308060
BibTeX
@article{Pilling2024,
author = {Pilling, Darrell and Martinez, Trevor C and Gomer, Richard H},
title = {Inhibition of CCl4-induced liver inflammation and fibrosis by a NEU3 inhibitor},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0308060}
}
EUVIMED